Immix Biopharma - IMMX Real Price to Acquire Entire Company

immixbio.com (IMMX) - corporate logo

Immix Biopharma, Inc. (IMMX) is a leading developer of CAR-T therapies for the treatment of myeloma and autoimmune pathologies, possessing immense scientific potential. The company's environmental business strategy involves implementing "green chemistry" principles to minimize energy consumption and ensure the safe disposal of chemicals. The Enterprise Value price history is recorded at 436.26. Currently, the company's research capacities are fully utilized, and its production facilities are prepared to scale up drug manufacturing volumes.

IMMX (Immix Biopharma) Total Company Value history from 11/23/2025 to 10/28/2026

Immix Biopharma - analytical breakdowns and key metrics (IMMX)

- price and consensus price forecast:
Stock Quotes Immix Biopharma Inc.|IMMX - Price Target Chart
- market capitalization data:
Market Valuation Immix Biopharma|IMMX - Real Price to Acquire Entire Company
- book capitalization data:
Equity per Share Immix Biopharma|IMMX - Company Book Value|Market-to-Book Ratio immixbio.com|IMMX - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Ratio Immix Biopharma, Inc.|IMMX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Immix Biopharma Inc.|IMMX - Company Debts|Debts to Book Value Immix Biopharma|IMMX - Company Long-Term Debt|Company Short-Term Debt Immix Biopharma
Fundamental valuation:Immix Biopharma, Inc. (IMMX)
Original product of Immix

The use of AI platforms and robotic screening in drug development optimizes costs for Immix Biopharma, Inc. (IMMX). The dynamics of the company's enterprise value (EV) reflect the actual acquisition price of the business. This metric sums market capitalization and debt, subtracting available cash. This allows for an asset valuation without distortions caused by reporting time lags. This indicator helps investors timely recognize stock overheating or fundamental shifts in the firm's value.

Competitors of Immix Biopharma, Inc. (IMMX)

ImmunityBio Inc - Real Price to Acquire Entire Company|IMCR: Total Company Value|Janux Corp (JANX) - Real Price to Acquire Entire Company|Real Price to Acquire Entire Company Arcus Biosciences, Inc.|ZYME (zymeworks.com) - Business Value|Total Company Value TNGX (Tango Therapeutics, Inc.)|Total Enterprise Value IOVA|Total Company Value Immatics Corp IMTX|Business Value Xencor Inc. (XNCR)|Compass Therapeutics - Enterprise Value|replimune.com - Real Price to Acquire Entire Company|LYEL (Lyell Immunopharma, Inc.) - Total Company Value|IPHA: Total Enterprise Value|pyxisoncology.com (PYXS) - Total Company Value|CGEN (Compugen) - Total Company Value|Total Company Value IOBT (IO Biotech, Inc.)|Total Enterprise Value sutrobio.com|INKT: Enterprise Value|Full Takeover Company Value werewolftx.com HOWL|ALXO: Real Price to Acquire Entire Company|CUE - Total Enterprise Value|Real Price to Acquire Entire Company PDS Biotechnology Corp (PDSB)|SONN - Value Adjusted for Debt and Cash|MAIA Biotechnology, Inc. - Enterprise Value|LIMN (Liminatus Pharma Inc.) - Company Buyout Price|Total Company Value LVTX|Real Price to Acquire Entire Company NXTC|Total Company Value LPTX (Leap Therapeutics, Inc.)|Real Price to Acquire Entire Company intensitytherapeutics.com INTS|Real Price to Acquire Entire Company SNSE (Sensei Biotherapeutics, Inc.)|Theriva Biologics Inc - Enterprise Value|Gritstone Bio (GRTS) - Total Company Value|KA: Business Value|Total Company Value NEXI|Total Enterprise Value Turnstone Biologics Corp.|Vaccinex - Real Price to Acquire Entire Company|Full Takeover Company Value Harpoon Therapeutics Inc (HARP)